. 2009 Oct;6(10):21–29.

Table 3.

Number needed to treat (NNT) analyses of data from 10 studies of children, adolescents, and adults With ADHD

STUDY	TREATMENT, SUBJECTS, AND SCALES^a	NNT
Biederman et al, 2007 (4 weeks)²⁷	LDX (n=214) vs. placebo (n=72). Children. % CGI responders^a	2
Greenhill et al, 2002 (3 weeks)²⁸	MR-MPH (n=155) vs. placebo (n=159). Children and adolescents. % CGI responders^a	3
Kratochvil et al, 2005 (5 weeks)²⁹	Atomoxetine + fluoxetine (n=127) vs. atomoxetine+placebo (n=46). Children and adolescents. % responders: ADHD-RS or CDRS-R scores 1 SD of age and sex norms	ADHD-RS, 12; CDRS-R, 6
Kuperman et al, 2001 (7 weeks)³⁰	SR-bupropion (n=11) vs. MPH (n=8) vs. placebo (n=8). Adults. % CGI responders^a	Bupropion vs. placebo, 3; MPH vs. placebo, 4
Pliszka et al, 2000 (3 weeks)³¹	MAS (n=20) vs. MPH (n=20) vs. placebo (n=18). Children. % CGI responders^a	MAS vs. placebo, 2; MPH vs. placebo, 3
Reimherr et al, 2007 (4 weeks)³²	OROS-MPH (n=47) vs. placebo. Crossover study. Adults. % responders: ≥50% improvement in WRAADDS scores	3
Riggs et al, 2004 (12 weeks)³³	Pemoline (n=34) vs. placebo (n=33). Adolescents. % CGI responders^a	5
Safren et al, 2005 (15 weeks)³⁴	Cognitive-behavioral therapy + ADHD medications (n=16) vs. ADHD medications (n=15). Adults. % CGI responders^a	2
Spencer et al, 2005 (6 weeks)³⁵	MPH (n=104) vs. placebo (n=42). Adults. % responders: % CGI responders^a + >30% reduction in AISRS scores	2
Weiss et al, 2006 (20 weeks)³⁵	DEX (n=23) vs. paroxetine (n=24) vs. placebo (n=26). Adults. % CGI responders^a	DEX vs. paroxetine, 2; vs. placebo, 2

Patients with CGI ratings of much or very much improved (score 1 or 2).